| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 148, 1203-1217, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
AJ Potgens, MC van Altena, NH Lubsen, DJ Ruiter and RM de Waal
Department of Pathology, University Hospital Nijmegen, The Netherlands.
Vascular permeability factor (VPF) is an important mediator of vascular development in tumors. Some human melanoma cell lines have a low VPF expression level in culture, but this level is upregulated when growing as a tumor in nude mice. Other melanoma lines have a constitutively high VPF expression. To compare the biological behavior of tumors with these two expression patterns, a human melanoma cell line with an inducible VPF expression was transfected with VPF expression constructs. In this way, several lines were obtained that constitutively produce either the soluble VPF121 or the matrix- associated VPF189 variant at levels of 4 to 30 times the VPF level in mature tumors derived from the parental line. The recombinant VPF RNA, which lacks most of the 5' noncoding sequences present in the endogenous VPF mRNA, was much more efficiently translated than the endogenous messenger. Upon injection in nude mice, all VPF-transfected lines developed tumors with aberrations in vascularization and in distribution of matrix components. In these tumors the blood vessels were hyperpermeable for an i.v. injected protein tracer. Transfection did not influence the in vitro growth rate of the cell lines, but the tumors from the VPF-transfected lines had higher growth rates in vivo than tumors from the parental line or the vector-transfected line. Although the incidence of lung metastasis was similar in all lines, the number of metastases per affected lung was significantly increased in mice carrying VPF-transfectant tumors. We conclude that the pattern and the level of VPF expression in a tumor are important determinants of the architecture and functionality of the vascular bed, but that overexpression of VPF does not necessarily lead to an increase of microvascular density or metastatic spread. The role of VPF in melanoma progression is obviously complex and may be difficult to derive in its generality from a single experimental model.
This article has been cited by other articles:
 |
|
 |
|
  R. Folberg, Z. Arbieva, J. Moses, A. Hayee, T. Sandal, S. Kadkol, A. Y. Lin, K. Valyi-Nagy, S. Setty, L. Leach, et al. Tumor Cell Plasticity in Uveal Melanoma: Microenvironment Directed Dampening of the Invasive and Metastatic Genotype and Phenotype Accompanies the Generation of Vasculogenic Mimicry Patterns Am. J. Pathol., October 1, 2006; 169(4): 1376 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarijs, M. van Dijk, D. J. Ruiter, and R. M. W. de Waal Functional and Morphologic Analysis of the Fluid-Conducting Meshwork in Xenografted Cutaneous and Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3013 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ruf, E. A. Seftor, R. J. Petrovan, R. M. Weiss, L. M. Gruman, N. V. Margaryan, R. E. B. Seftor, Y. Miyagi, and M. J. C. Hendrix Differential Role of Tissue Factor Pathway Inhibitors 1 and 2 in Melanoma Vasculogenic Mimicry Cancer Res., September 1, 2003; 63(17): 5381 - 5389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Hess, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix Phosphoinositide 3-Kinase Regulates Membrane Type 1-Matrix Metalloproteinase (MMP) and MMP-2 Activity during Melanoma Cell Vasculogenic Mimicry Cancer Res., August 15, 2003; 63(16): 4757 - 4762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, Z. Ai, M. Rasmussen, P. Bajcsy, L. Auvil, M. Welge, L. Leach, S. Vangveeravong, A. J. Maniotis, and R. Folberg Three-Dimensional Reconstruction of Extravascular Matrix Patterns and Blood Vessels in Human Uveal Melanoma Tissue: Techniques and Preliminary Findings Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2834 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Clarijs, I. Otte-Holler, D. J. Ruiter, and R. M. W. de Waal Presence of a Fluid-Conducting Meshwork in Xenografted Cutaneous and Primary Human Uveal Melanoma Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 912 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. B. Seftor, E. A. Seftor, N. Koshikawa, P. S. Meltzer, L. M. G. Gardner, M. Bilban, W. G. Stetler-Stevenson, V. Quaranta, and M. J. C. Hendrix Cooperative Interactions of Laminin 5 {gamma}2 Chain, Matrix Metalloproteinase-2, and Membrane Type-1-Matrix/Metalloproteinase Are Required for Mimicry of Embryonic Vasculogenesis by Aggressive Melanoma Cancer Res., September 1, 2001; 61(17): 6322 - 6327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Straume and L. A. Akslen Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas Am. J. Pathol., July 1, 2001; 159(1): 223 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsuzuki, D. Fukumura, B. Oosthuyse, C. Koike, P. Carmeliet, and R. K. Jain Vascular Endothelial Growth Factor (VEGF) Modulation by Targeting Hypoxia-inducible Factor-1{{alpha}} {->} Hypoxia Response Element {->} VEGF Cascade Differentially Regulates Vascular Response and Growth Rate in Tumors Cancer Res., November 1, 2000; 60(22): 6248 - 6252. [Abstract] [Full Text]
|
|
|
|
|
|
E. K. Rofstad and E. F. Halsør Vascular Endothelial Growth Factor, Interleukin 8, Platelet-derived Endothelial Cell Growth Factor, and Basic Fibroblast Growth Factor Promote Angiogenesis and Metastasis in Human Melanoma Xenografts Cancer Res., September 1, 2000; 60(17): 4932 - 4938. [Abstract] [Full Text]
|
|
|
|
|
|
R. Folberg, M. J. C. Hendrix, and A. J. Maniotis Vasculogenic Mimicry and Tumor Angiogenesis Am. J. Pathol., February 1, 2000; 156(2): 361 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yoshiji, S. Kuriyama, D. K. Ways, J. Yoshii, Y. Miyamoto, M. Kawata, Y. Ikenaka, H. Tsujinoue, T. Nakatani, M. Shibuya, et al. Protein Kinase C Lies on the Signaling Pathway for Vascular Endothelial Growth Factor-mediated Tumor Development and Angiogenesis Cancer Res., September 1, 1999; 59(17): 4413 - 4418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O SCHLINGEMANN and V. W M VAN HINSBERGH Role of vascular permeability factor/vascular endothelial growth factor in eye disease Br. J. Ophthalmol., June 1, 1997; 81(6): 501 - 512. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yuan, Y. Chen, M. Dellian, N. Safabakhsh, N. Ferrara, and R. K. Jain Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody PNAS, December 10, 1996; 93(25): 14765 - 14770. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
